Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCCAP.L Regulatory News (CCAP)

  • There is currently no data for CCAP

Trading Statement

14 Jul 2016 07:00

RNS Number : 1245E
Charlemagne Capital Limited
14 July 2016
 

14 July 2016

 

 

Interim Management Statement for the Six Months Ended 30 June 2016

 

Charlemagne Capital Limited (the "Group") sets out below the key revenue items and assets under management ("AuM") for the first six months of its current financial year. It is expected that the interim financial results will be announced in September 2016.

 

Key highlights and Group AuM

 

§ As at 30 June 2016, Group AuM were US$2.1 billion

§ Net management fees of US$9.0 million for the six months ended 30 June 2016

· The Group remains well-capitalised with a strong and liquid balance sheet

 

The table below sets out the Group's AuM as at 30 June 2016 and the movements experienced in each product range in the period since 1 January 2016.

 

01-Jan-16

Net Subscriptions

Net Performance

30-Jun-16

Movement In

AuM (US$m)

(US$m)

(%)

(US$m)

(%)

AuM (US$m)

Period (%)

Magna

508

(45)

(8.9)

30

6.2

493

(3.0)

OCCO

493

23

4.7

25

5.0

541

9.7

Institutional

805

65

8.1

85

10.1

955

18.6

Specialist

91

11

12.1

(6)

(6.2)

96

5.5

Total

1,897

54

2.8

134

7.0

2,085

9.9

 

Notes:

Closing AuM is stated as including all subscription and redemption orders received for the relevant funds as at the close of the period but not processed until the first dealing date of the following period.

 

Unaudited revenue numbers for the six months ended 30 June 2016

 

Net management fees receivable were US$9.0 million compared with US$10.0 million for the previous six months and US$10.7 million for the comparable period of 2015, reflecting the fall in average AuM since that period and a small reduction in net revenue margin. OCCO management fees, which are subject to a minority interest, accounted for 46% of total net management fee income during the period.

 

Crystallised performance fees were US$0.3 million compared with US$0.7 million for the comparative period in 2015. Accruing performance fees1 for 2016 which have not crystallised were US$8.5 million, US$6.6 million of which relates to OCCO and are subject to a minority interest, compared with US$0.9 million as at the same date in 2015. Other income inclusive of gains/losses on investments held and foreign exchange was overall negative US$0.2 million for the period compared with positive income of US$0.4 million for the same period last year.

 

 

_________________________________________________________________________

1Performance fees accrue throughout the reporting period in the accounts of each relevant fund. It is the group's accounting policy only to recognise such revenues as they crystallise at the year-end date of the fund or, in certain cases, on redemption. Levels of accrued performance fees at any particular time should not be seen as necessarily indicative of the eventual crystallised figures, especially in periods of above average market volatility.

Summary

 

Emerging markets ended the first half up having suffered a sharp decrease in values in the first two months and then recovered at the end of the first quarter. The MSCI Emerging markets index was up by 6.4% in US$ over the full half year after being down 6.6% at the end of February.

 

Overall flows for the Group were positive which is pleasing against a backdrop of continued industry outflows; however average AuM dipped in the first quarter and was down over the full period to US$1.9 billion compared to US$2.2 billion in the corresponding period last year and US$2.1 billion for 2015 as a whole. This current average level of AuM remains below the level required to ensure sustainable profits on a recurring management fee basis.

 

Outlook

 

The first half of 2016 saw emerging markets (EM) equities outperform developed markets, reversing a five-year trend. While the impact of the Brexit vote on developed markets was a sting in the tail at the end of the period, EM had led the way even before the 23rd June. There are several reasons for this. EM has been increasingly an unloved, and therefore under owned, asset class, trading at a historically low price to book ratio. The shrinking EM growth premium looks set to widen again, as countries like Brazil and Russia start to recover from deep slumps whilst at the same time growth in the likes of Japan and the UK are slowing. There are signs that market analysts are at last being more realistic (cautious) about estimating corporate earnings, which allows at least some chance that they might subsequently be exceeded.

 

The Group's investment performance remains strong. It was affected in the spring by the beta rally in commodity shares, which we generally don't own due to business models, ownership structures and earnings volatility. This didn't help our growth style. Despite this, five of the seven Magna strategies were in the top half of their respective FactSet Morningstar peer groups over the six months and six out of seven over 12 months.

 

The economic impact of an eventual Brexit on EMs should be modest, except in the remote event that globalisation is comprehensively reversed or there are other geopolitical shocks to the global economy. However, the UK vote means that policy risk in the heart of Europe may remain elevated, for many years, at levels unthinkable just a few years ago. The rise in populism and antiglobalism is also likely to be a key factor in the forthcoming US election. These factors could destabilise developed economies at a time when the economics of the EM countries are beginning to recover.

 

 

Enquiries:

 

Charlemagne Capital

Jayne Sutcliffe, Chief Executive

Tel. 020 7518 2100

Lloyd Jones, Finance Director

Tel. 01624 640200

N+1 Singer

Tel. 020 7496 3000

Nic Hellyer

Gillian Martin

Smithfield Consultants

Tel. 020 7360 4900

John Kiely

Ged Brumby

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBLGDRRBBBGLX
Date   Source Headline
15th Mar 20167:01 amRNSDividend Declaration
15th Mar 20167:00 amRNSFinal Results
17th Feb 20163:07 pmRNSTR1 - Notification of Major Interest in Shares
19th Jan 20167:00 amRNSTrading Statement
27th Nov 201511:28 amRNSForm 8.3 - Al Noor Hospitals Group PLC
26th Nov 201510:42 amRNSForm 8.3 - Al Noor Hospitals Group PLC
25th Nov 201510:48 amRNSForm 8.3 - Al Noor Hospitals Group PLC
23rd Nov 201511:56 amRNSForm 8.3 - Al Noor Hospitals Group PLC
19th Nov 201510:56 amRNSForm 8.3 -NMC Health PLC
18th Nov 201511:29 amRNSForm 8.3 - Al Noor Hospitals Group PLC
17th Nov 201510:25 amRNSForm 8.3 - NMC Health PLC
17th Nov 20159:42 amRNSForm 8.3 - Al Noor Hospitals Group PLC
17th Nov 20159:35 amRNSForm 8.3 - NMC Health Plc
9th Nov 201511:38 amRNSForm 8.3 - Al Noor Hospitals
4th Nov 20154:32 pmRNSForm 8.3 - NMC Health Plc
28th Oct 201511:34 amRNSForm 8.3 - Al Noor Hospitals
28th Oct 201511:30 amRNSForm 8.3 - NMC Health PLC
16th Oct 201511:27 amRNSHolding(s) in Company
9th Oct 20157:00 amRNSQ3 2015 AUM Update
22nd Sep 20157:01 amRNSDividend Declaration
22nd Sep 20157:00 amRNSHalf Yearly Report
15th Jul 20157:00 amRNSInterim Management Statement
19th Jun 20156:00 pmRNSHolding(s) in Company
19th Jun 201512:17 pmRNSResult of AGM
15th May 20153:05 pmRNSAnnual Report and Notice of AGM
29th Apr 20156:06 pmRNSHolding(s) in Company
10th Apr 20157:00 amRNSQ1 2015 AUM Update
30th Mar 20159:00 amRNSQuadruple Lipper Award Win for Charlemagne Capital
17th Mar 20157:05 amRNSDividend Declaration
17th Mar 20157:00 amRNSFinal Results
13th Jan 20157:00 amRNSTrading Statement
23rd Dec 20144:28 pmRNSDirector/PDMR Shareholding
10th Oct 20147:00 amRNSQ3 2014 AUM Update
18th Sep 201410:38 amRNSDirector/PDMR Shareholding
17th Sep 201411:46 amRNSDirector/PDMR Shareholding
16th Sep 20147:30 amRNSDividend Declaration
16th Sep 20147:00 amRNSHalf Yearly Report
15th Jul 20147:00 amRNSInterim Management Statement
20th Jun 20144:02 pmRNSResult of AGM
19th May 20149:20 amRNSMAGNA MENA FUND REACHES 3 YEAR ANNIVERSARY
14th May 20142:38 pmRNSNotice of AGM
14th May 20147:00 amRNSDirector/PDMR Shareholding
9th May 20148:16 amRNSTriple Lipper Award Win for Charlemagne Capital
28th Apr 20143:27 pmRNSChange to Significant Shareholding
25th Apr 201412:49 pmRNSHolding(s) in Company
25th Apr 201410:30 amRNSHolding(s) in Company
8th Apr 20147:00 amRNSQ1 2014 AUM Update
18th Mar 20147:05 amRNSDividend Declaration
18th Mar 20147:00 amRNSFinal Results
14th Jan 20144:12 pmRNSAdditional Listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.